

								
	(A404					maying@tmu.edu.cn		
2010 9 2015 7 2005 10 2009 6								
2015 7								

1. Wu J, Li W, Zheng Z, Lu X, Zhang H, **Ma Y***, et al. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxyethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. *J Biomol Struct Dyn.* 2021;39(4):1174-88.
2. Zhou L, Ma YC, Tang X, Li WY, **Ma Y***, Wang RL. Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and post-analysis. *J Biomol Struct Dyn.* 2021;39(1):45-62.
3. Li WY, **Ma Y***, Li HX, Lu XH, Du S, Ma YC, et al. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation. *Bioorg Chem.* 2020;105:104391.
4. Liu WS, Yang B, Wang RR, Li WY, Ma YC, Zhou L, **Ma Y***, et al. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors. *Bioorg Chem.* 2020;100:103875.
5. Ma YC, Yang B, Wang X, Zhou L, Li WY, Liu WS, **Ma Y***, et al. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis. *J Biomol Struct Dyn.* 2020;38(15):4432-48.
6. Wu J, Sun Y, Zhou H, **Ma Y***, Wang R. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. *J Biomol Struct Dyn.* 2020;38(11):3156-65.
7. Wu JW, Zhang H, Li WY, Tang X, Li HL, Lu XH, **Ma Y*** et al. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace

- 13.Sun Y-Z, Chen X-B, Wang R-R, Li W-Y, **Ma Y***. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study. *Journal of Cellular Biochemistry*. 2019;120(4):5949-61.
- 14.Liu W-S, Wang R-R, Li W-Y, Rong M, Liu C-L, **Ma Y***, et al. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. *J Biomol Struct Dyn*. 2019:1-12.
- 15.Liu W-S, Jin W-Y, Zhou L, Lu X-H, Li W-Y, **Ma Y***, et al. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. *Journal of Computer-Aided Molecular Design*. 2019;33(8):759-74.
- 16.Liu WS, Wang RR, Sun YZ, Li WY, Li HL, Liu CL, **Ma Y***, et al. Exploring the effect of y molecular docking and molecular dynamics simulation. *Journal of Cellular Biochemistry*. 2019.
- 17.Du S, Yang B, Wang X, Li W-Y, Lu X-H, Zheng Z-H, **Ma Y***, et al. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation.*J Biomol Struct Dyn*. 2019:1-14.
- 18.Zhu Y, Han Y, **Ma Y***, Yang P. ADME/toxicity prediction and antitumor activity of novel nitrogenous heterocyclic compounds designed by computer targeting of alkylglycerone phosphate synthase. *Oncol Lett*. 2018.
- 19.Ma Y, Li H-L, Chen X-B, Jin W-Y, Zhou H, **Ma Y***, et al. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B. *Comput Biol Chem*. 2018;73:1-12.
- 20.Li W-Y, Wei H-Y, Sun Y-Z, Zhou H, **Ma Y***, Wang R-L*. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study. *Journal of Cellular Biochemistry*. 2018;119(12):9941-56.
- 21.Jin W-Y, **Ma Y***, Li W-Y, Li H-L, Wang R-L. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics. *Comput Biol Chem*. 2018;73:179-88.
- 22.Liu X, Jing Z, Jia W-Q, Wang S-Q, **Ma Y***, Xu W-R, et al. Identification dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. *Journal of Biomolecular Structure and Dynamics*. 2017;36(11):2988-3002.
- 23.Li H-L, **Ma Y***, Zheng C-J, Jin W-Y, Liu W-S, Wang R-L. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study. *Journal of Biomolecular Structure and Dynamics*. 2017;36(14):3856-68.
- 24.**Ying Ma**[#], Hui-Yu Wei[#], Yu-Ze Zhang, Wen-Yan Jin, Hong-Lian Li, Hui Zhou, Xian-Chao Cheng, and Run-Ling Wang*. Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors [J]. *Oncotarget*, 2017, 8(24); 38466-38481.
- 25.Hong-Lian Li[#], **Ying Ma**[#], Ying Ma, Yu Li, Xiu-Bo Chen, Wei-Li Dong, and Run-Ling Wang*.The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches [J]. *Oncotarget*, 2017, 8 (20); 33225-33240.

1. SHP2 D61G E76K
(16JCZDJC32500) 2016.04-2019.03
2. 81611130090 SHP2
2016.1-2018.12
3. PTP-1B PPAR- PPAR- □
20972112 20972112